摘要
目的:评价氯氮平口腔崩解片治疗精神分裂症的疗效和安全性。方法:将60例精神分裂症患者随机分为研究组(氯氮平口腔崩解片治疗)30例,对照组(利培酮治疗)30例,观察8周,于治疗前和治疗2、4、8周末采用阳性和阴性症状量表(PANSS)、副反应量表(TESS)评定疗效和安全性。结果:两组治疗8周末PANSS总分和各因子分均有不同程度下降,两组疗效差异无统计学意义(P>0.05),但研究组显效快,不良反应小。结论:氯氮平口腔崩解片对精神分裂症的疗效和利培酮相仿,但起效快且不良反应小。
Objective:To explore effects and safety of clozapine orally disintegrating tablets in treatment of schizophrenia. Methods :60 Schizophrenics were randomly divided into research group (n = 30, taking clozapine orally disintegrating tablets) and con- trol group (n= 30, taking risperidone) and observed for 8 weeks. The clinical efficacies and safety were assessed with the positive and negative syndrome scale (PANSS) and treatment emergent symptom scale (TESS) before and 2, 4 and 8 weeks after the treatment. Re- sults: 8 weeks after the treatment, the total and all factor scores of PANSS of the two groups decreased, and there was no significant difference between the two groups ( P〉0.05 ). Moreover, research group was quick in the effects and low in the adverse reactions. Conclusions : Clozapine orally disintegrating tablets is similar with Risperidone in the efficacy of Schizophrenia, but the side effects are less and the symptoms are improved quickly.
出处
《中国民康医学》
2013年第19期38-39,共2页
Medical Journal of Chinese People’s Health
关键词
精神分裂症
氯氮平口腔崩解片
利培酮
对照研究
Schizophrenia
Clozapine orally disintegrating tablets
Risperidone
Control study